Compare FONR & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FONR | WHWK |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 95.2M |
| IPO Year | 1995 | N/A |
| Metric | FONR | WHWK |
|---|---|---|
| Price | $18.54 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 66.4K | ★ 98.3K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $104,351,318.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | ★ 1.43 | N/A |
| 52 Week Low | $12.00 | $1.39 |
| 52 Week High | $18.86 | $3.77 |
| Indicator | FONR | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 66.13 |
| Support Level | $18.49 | $1.89 |
| Resistance Level | $18.73 | $3.77 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 20.92 | 91.95 |
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.